Ketamine pills could ease debilitating CRPS pain – new trial underway
NCT ID NCT06419985
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 2 trial will test whether extended-release ketamine tablets can reduce pain in 65 adults with complex regional pain syndrome (CRPS), a chronic condition causing severe, often burning pain. Participants will take either 80 mg or 160 mg of ketamine daily for several weeks. The study is open-label, meaning everyone knows they are getting the drug, and it focuses on pain scores, quality of life, and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEX REGIONAL PAIN SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pain Center, Keck Medical Center of University of Southern California
Los Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ketamine extended-release tablets
What this could lead to
If successful, this could provide a new oral treatment option to ease chronic pain for people with complex regional pain syndrome.
What could go wrong
This is an early-phase, open-label trial with no placebo group, so results may be influenced by expectation. The small size (65 people) also limits how broadly findings can be applied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.